The researchers looked at data from 4,286 people -- out of a total of 17,605 from the landmark Semaglutide and Cardiovascular Outcomes (SELECT) trial who were randomly assigned either semaglutide or a placebo -- who were followed up over an average of more than three years.
The researchers looked at data from 4,286 people -- out of a total of 17,605 from the landmark Semaglutide and Cardiovascular Outcomes trial who were randomly assigned either semaglutide or a placebo -- who were followed up over an average of more than three years.
They found that semaglutide was linked to a 28% reduction in major adverse cardiac events , as well as a 24% reduction in cardiovascular disease-related deaths for this subgroup of people with pre-existing heart failure, and a 19% reduction in deaths of any cause. Semaglutide, a GLP-1 receptor agonist, simulates the functions of the body's natural incretin hormones, which help to lower blood sugar levels after a meal. It was initially prescribed for adults with type 2 diabetes.
The researchers said the reduction in all-cause mortality in all heart failure groups"suggests the potential for other, as yet unknown, benefits."
Stroke Prevention Vioxx Diseases And Conditions Cholesterol Diabetes Chronic Illness Personalized Medicine
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Micah Parsons reveals weight loss; down to college playing weightDallas Cowboys superstar Micah Parsons is taking on a versatile role in new defensive coordinator Mike Zimmer's system, and he'll be lighter on his feet.
Read more »
Who should pay Dallas' crossing guards?Members of council raised concerns about whether schools or the state should be helping to foot the bill at 286 busy Dallas school crossings.
Read more »
A Man’s Rapid Weight Loss From Obesity Drug Led to Heart ProblemsA case report highlights the danger of mixing certain medications with the newest generation of weight-loss drugs.
Read more »
Obesity Drug Case Study Links Man's Heart Problems With Extreme Weight LossThe Best in Science News and Amazing Breakthroughs
Read more »
Eli Lilly's weight loss drug Zepbound cuts heart failure risks in late-stage studyThe data adds to mounting evidence that Zepbound and other popular GLP-1 drugs have health benefits beyond promoting weight loss and regulating blood sugar.
Read more »
Weight Loss Drug Zepbound Could Lower Heart Failure Risks, Eli Lilly SaysTy Roush is a New York City-based breaking news reporter who frequently covers Russia’s invasion of Ukraine, the automotive industry and sports money. He joined Forbes in 2022 and has covered Exxon acquiring Pioneer for nearly $60 billion, a mysterious respiratory illness affecting dogs across the U.S.
Read more »